Loading…
Based on limited metadata, this warning letter was issued to University Fertility Laboratory, Inc., a biologics manufacturer, on May 30, 2019. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The letter falls under FDA's biologics regulatory scope, which typically covers products like cellular therapies, tissue products, and other biological preparations used in fertility treatment. Additional context from the complete warning letter would be needed to identify the particular compliance issues cited.